(NP (-LRB- -LCB-) (NP (JJ Molecular) (NNS mechanisms)) (PP (IN of) (NP (JJ age-related) (NN lymphocyte) (NN dysfunction))) (-RRB- -RCB-))
(S (NP-SBJ-14 (NN Aging)) (VP (VBZ is) (ADVP (RB classically)) (VP (VBN accompanied) (NP (-NONE- *-14)) (PP (IN by) (NP-LGS (NP (DT a) (NN dysregulation)) (PP (IN of) (NP (DT the) (JJ immunologic) (NN machinery))))))) (. .))
(S (PP (IN As) (NP (DT a) (NN consequence))) (, ,) (NP-SBJ (NP (DT the) (JJ immune) (NN response)) (VP (VBN developed) (NP (-NONE- *)) (PP (IN in) (NP (JJ senescent) (NNS organisms))))) (VP-COOD (VP (VBZ is) (ADVP-TMP-15 (RB usually)) (ADJP-PRD-16 (JJ inappropriate))) (, ,) (VP (ADVP-TMP=15 (RB often)) (ADJP-PRD=16 (JJ inefficient))) (, ,) (VP (ADVP-TMP=15 (RB sometimes)) (ADJP-PRD=16 (JJ aberrant))) (, ,) (CC and) (VP (ADVP=15 (RB potentially)) (ADJP-PRD=16 (JJ detrimental)))) (. .))
(S (NP-SBJ-17 (DT The) (JJ age-associated) (JJ immune) (NN dysfunction)) (VP-COOD (VP (MD may) (VP (VB be) (VP (VBN implicated) (NP (-NONE- *-17)) (PP (TO to) (NP (DT some) (NN degree))) (PP (IN in) (NP (NP (DT the) (JJ extreme) (NN susceptibility)) (PP (IN of) (NP (DT the) (JJ elderly))) (PP (TO to) (NP-COOD (NP (NN infection)) (CC and) (NP (NN neoplasia))))))))) (CC and) (VP (MD may) (ADVP (RB even)) (VP (VB participate) (PP (IN in) (NP (NP (JJ various) (NNS aspects)) (PP (IN of) (NP (NN senescence)))))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ current) (NN understanding)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBG underlying) (NP (NN immunosenescence)))))) (VP (VBZ is) (ADVP (RB still)) (ADJP-PRD (JJ fragmentary))) (. .))
(S (NP-SBJ (DT The) (ADJP (ADVP (RBS most) (RB extensively)) (VBN studied)) (NN phenomenon)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ progressive) (NN decline)) (PP (IN in) (NP (NP (DT the) (JJ proliferative) (NNS capacities)) (PP (IN of) (NP (NN T) (NNS lymphocytes))))) (PP (IN with) (NP (NN aging))))) (. .))
(S (NP-SBJ (NP (DT The) (NN loss)) (PP (IN of) (NP (NP (JJ proliferative) (NN potential)) (PP (IN in) (NN response) (TO to) (NP (JJ antigenic) (NN challenge)))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ characteristic) (NN feature)) (PP (IN of) (NP (JJ immune) (NN senescence))))) (. .))
(S (NP-SBJ-18 (PRP It)) (VP (VBZ is) (ADVP (RB directly)) (VP (VBN implicated) (NP (-NONE- *-18)) (PP (IN in) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (DT the) (JJ age-related) (JJ immune) (NN deficiency))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN review)))) (VP (VBZ is) (S-PRD (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB show) (SBAR (WHADVP-19 (WRB how)) (S (NP-SBJ (NP (DT the) (NN accumulation)) (PP (IN of) (NP (JJ various) (JJ biochemical) (NNS lesions))) (PP (IN with) (NP (VBG advancing) (NN age)))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT the) (NN failure)) (PP (IN of) (NP (NP (DT a) (JJ critical) (NN cell) (NN function)) (, ,) (RB namely) (NP (DT the) (JJ activation-induced) (NN lymphocyte) (NN proliferation)))))) (ADVP (-NONE- *T*-19))))))))) (. .))
(S (NP-SBJ-20 (NP (DT The) (JJ biochemical) (NNS modifications)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN defect)) (PP (IN in) (NP (NP-COOD (NP (NN transduction)) (CC and) (NP (NN execution))) (PP (IN of) (NP (DT the) (JJ proliferative) (NN signal))))))))) (VP (VBP are) (VP (VBN analyzed) (NP (-NONE- *-20)) (PP (IN as) (NP (NP (DT a) (NN function)) (PP (IN of) (NP (NN age))))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ multiple) (NNS alterations)) (VP (VBN observed) (NP (-NONE- *)) (PP (IN on) (NP (DT the) (JJ various) (JJ biochemical) (NNS pathways))))) (VP (MD may) (VP (VB appear) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NP (DT a) (JJ unique) (JJ deleterious) (NN mechanism)) (ADJP (ADVP (RBR more) (RB fundamentally)) (JJ related) (PP (TO to) (NP (NP (DT the) (NN process)) (PP (IN of) (NP (NP (NN senescence)) (PP (JJ such) (IN as) (NP (DT the) (NN inability) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB cope) (PP (IN with) (NP (JJ oxidative) (NN stress))))))))))))))))))) (. .))
